

## PROXY FORM

in accordance with Chapter 7 Section 54 (a) of the Swedish Companies Act

I hereby appoint the proxy stated below, or whomever he or she may appoint, to vote on my behalf for all my shares in Hansa Biopharma AB (publ), Reg. No. 556734-5359, at the Annual General Meeting of Hansa Biopharma AB (publ) on June 1, 2026.

### Proxy

Name of the proxy	Personal identity number/Date of birth
Address	
Postal code and city	Telephone number

### Signature by the shareholder

Name of the shareholder	Personal identity number/Date of birth/Registration number
Place and date	Telephone number
Signature*	

\*If signing for a company, a clarification of signature shall be included above and an up to date certificate of registration (or the equivalent) shall be enclosed to the completed proxy form.

Please note that a shareholder shall give the company notice of attendance – as set out in the notice convening the meeting – even if the shareholder intends to exercise his or her voting rights through a proxy.

The completed proxy form (with any enclosures) may be submitted via e-mail to [hansabiopharma@vinge.se](mailto:hansabiopharma@vinge.se) or by post to Advokatfirman Vinge KB, Att: Johannes Ekbohm, Box 1703, SE-111 87 Stockholm, Sweden, together with the notice of attendance. For the avoidance of doubt, if the shareholder does *not* intend to exercise his or her voting rights through a proxy, the proxy form does not have to be submitted.

#### ***Processing of personal data***

For information on how your personal data is processed, see

[www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf](http://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf).